Yasushi Kawamata

Yasushi Kawamata

Auto-generated profile, based on publicly available information

Yasushi Kawamata

Department of Psychiatry Dokkyo Medical University School of Medicine Mibu Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
NYNorio Yasui-Furukori
Norio Yasui-Furukori
YKYasushi Kawamata
Yasushi Kawamata
TSTaro Sasaki
Taro Sasaki
SYSaaya Yokoyama
Saaya Yokoyama
HOHiroaki Okayasu
Hiroaki Okayasu
KSKazutaka Shimoda
Kazutaka Shimoda
Background: Recent pharmacoepidemiology data show an increase in the proportion of patients receiving second-generation antipsychotic (SGA) monotherapy, but no studies have analyzed the same patients over a long period of time. Therefore, in this study, we retrospectively evaluated schizophrenia patients with available data for 20 years to determine whether the drug treatments in the same patients have changed in the past 20 years. Methods: The study began in April 2021 and was conducted in 15 psychiatric hospitals in Japan. Schizophrenia patients treated in the same hospital for 20 years were retrospectively examined for all prescriptions in 2016, 2011, 2006, and 2001 (ie, every 5 years). Results: The mean age of the 716 patients surveyed in 2021 was 61.7 years, with 49.0% being female. The rate of antipsychotic monotherapy use showed a slight increasing trend over the past 20 years; the rate of SGA use showed a marked increasing trend from 28.9% to 70.3% over the past 20 years, while the rate of SGA monotherapy use showed a gradual increasing trend over the past 20 years. The rates of concomitant use of anticholinergics, antidepressants, anxiolytics/sleep medications, and mood stabilizers showed decreasing, flat, flat, and flat trends over the past 20 years, respectively. Conclusion: The results of this study showed a slow but steady substitution of SGAs for first-generation antipsychotics (FGAs) over time, even in the same patients.

29 March 2025 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
YKYasushi Kawamata
Yasushi Kawamata
KOKazutaka Ohi
Kazutaka Ohi
SISatsuki Ito
Satsuki Ito
NHNaomi Hasegawa
Naomi Hasegawa
YYYuka Yasuda
Yuka Yasuda
RHRyota Hashimoto
Ryota Hashimoto

20 November 2024 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
YIYugo Ishihara
Yugo Ishihara
NSNorio Sugawara
Norio Sugawara
YKYasushi Kawamata
Yasushi Kawamata
NYNorio Yasui‐Furukori
Norio Yasui‐Furukori
Aim: There are limited reports regarding psychotropic prescriptions in first‐visit patients with major depressive disorder (MDD). The objective of this study is to clarify the prescription patterns of psychotropics and their association with symptoms among first‐visit patients with MDD in Japan. Methods: In this cross‐sectional analysis, we examined 376 first‐visit patients diagnosed with MDD. Depressive symptoms were evaluated using the Quick Inventory of Depressive Symptomatology Japanese version (QIDS‐J). To assess personality traits, we administered the Japanese version of the Ten Item Personality Inventory (TIPI‐J), and psychotic symptoms were evaluated using the PRIME Screen‐Revised (PS‐J). Results: Among the first‐visit patients with MDD, 31.4% (118/376) were prescribed antidepressants, and 18.1% (68/376) received benzodiazepines. Overall, 40.2% (151/376) of the patients were prescribed at least one psychotropic medication. In a multivariate logistic regression model using the forced entry method, missing data on educational attainment and the view of myself domain of the QIDS‐J were negatively associated, while the concentration/decision‐making domain of the QIDS‐J was positively associated with antidepressant prescription. Conclusion: More than half of the first‐visit patients did not receive any psychotropic medication. Psychiatrists appear to consider specific symptoms and personality traits when deciding whether to prescribe medications, which may also be influenced by patient preferences. Further studies, including longitudinal analyses, are needed to explore these associations in more detail.

23 February 2026 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
THToru Horinouchi
Toru Horinouchi
YAYusuke Arai
Yusuke Arai
NHNaomi Hasegawa
Naomi Hasegawa
HMHiroyuki Muraoka
Hiroyuki Muraoka
KYKazuhiko Yamamuro
Kazuhiko Yamamuro
RHRyota Hashimoto
Ryota Hashimoto

5 March 2024 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
ASAoi Sato
Aoi Sato
NSNorio Sugawara
Norio Sugawara
YKYasushi Kawamata
Yasushi Kawamata
NYNorio Yasui‐Furukori
Norio Yasui‐Furukori
Aim: There is limited evidence regarding predictors of changes in suicidal ideation (SI) in patients with major depressive disorder (MDD). The objective of this study was to describe changes in SI over a 6‐month period and identify their predictors from naturalistic observations of MDD patients.Methods: In the cross‐sectional analysis, we examined 257 patients with MDD at the first‐visit assessment. Among the patients, 119 who completed the 6‐month assessment (completers) were included in the longitudinal analysis. For the evaluation of depressive symptoms, including SI, the Quick Inventory of Depressive Symptomatology‐Japanese version was administered at both the first‐visit and follow‐up assessments. At baseline, we also administered the Japanese version of the Ten Item Personality Inventory to assess personality traits and the PRIME Screen‐Revised to assess psychotic symptoms.Results: In the cross‐sectional analysis of first‐visit patients, 36.2% (93/257) exhibited SI. Among completers, 14.3% (17/119) had prolonged SI. Among the completers with SI at the first‐visit assessment, 38.6% (17/44) had SI at the follow‐up assessment (prolonged SI). In linear regression models including all completers, prolonged SI was positively associated with endorsement of suspiciousness/persecutory ideas and negatively associated with higher age.Conclusion: More than one‐third of completers who had SI at the first‐visit assessment experienced prolonged SI (SI at follow‐up). Our findings can help clinicians predict the course of MDD by identifying associated demographic and clinical characteristics.

1 July 2025 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
RIRui Inano
Rui Inano
NSNorio Sugawara
Norio Sugawara
YKYasushi Kawamata
Yasushi Kawamata
NYNorio Yasui-Furukori
Norio Yasui-Furukori
Purpose: There are limited reports, particularly in naturalistic settings, regarding predictors of clinical outcomes in patients with major depressive disorder (MDD). The objective of this observational, retrospective study is to describe 6-month clinical outcomes and identify their predictors among patients with MDD in Japan. Patients and methods: A total of 546 patients diagnosed with MDD at their first visit were enrolled in this naturalistic follow-up study, of whom 217 completed follow-up assessments at six months. Depressive symptoms were measured using the Japanese Quick Inventory of Depressive Symptomatology (QIDS-J). Potential predictors, including demographic characteristics, personality traits (assessed using the Ten Item Personality Inventory-Japanese version [TIPI-J]), and psychotic symptoms (measured by the PRIME Screen-Revised [PS-R]), were analyzed. Results: Among the 217 follow-up completers, 38% achieved response, and 20% reached remission. Persistent symptoms, particularly mid-nocturnal insomnia, remained prevalent at follow-up. Higher baseline depressive severity, presence of view of myself symptom, endorsement of suspiciousness/persecutory ideas, and lower educational attainment were consistently associated with greater depressive symptom severity at six months. Additionally, a robust association was observed between openness to experience and remission, while absence of view of myself symptom and endorsement of first-rank symptoms consistently predicted remission. Conclusion: This study identified significant predictors of clinical outcomes in MDD patients over a 6-month period. These findings underscore the importance of considering baseline symptoms, personality traits, and psychosocial factors in predicting MDD outcomes, informing more tailored treatment strategies in real-world clinical practice.